文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than
侵权投诉

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than

Anti-vascularendothelialgrowthfactortherapyforneovascularoculardiseasesotherthanage-relatedmaculardegeneration

ThomasA.CiullaaandPhilipJ.Rosenfeldb

VitreoretinalService,MidwestEyeInstitute,Indianapolis,IndianaandbDepartmentofOphthalmology,BascomPalmerEyeInstitute,

UniversityofMiamiMillerSchoolofMedicine,Miami,Florida,USA

CorrespondencetoThomasA.Ciulla,MD,VitreoretinalService,MidwestEyeInstitute,201PennsylvaniaParkway,Indianapolis,IN46280,USA

Tel:+13175060334;fax:+13178171898;e-mail:thomasciulla@yahoo.com

CurrentOpinioninOphthalmology2009,20:166–174

a

Purposeofreview

Anti-vascularendothelialgrowthfactor(anti-VEGF)therapiesthatarrestchoroidalangiogenesisandreducevascularpermeabilityhaverevolutionizedclinicalpracticesforneovasculareyediseases.Thisreviewdescribesanti-VEGFstrategiesthatarebeingevaluatedinoculardiseases,otherthanneovascularage-relatedmaculardegeneration,inwhichneovascularizationplaysacriticalroleinpathogenesis.Recent ndings

Earlystudiesoftheanti-VEGFagents,pegaptanibsodium,ranibizumab,bevacizumab,VEGFtrap,andbevasiranibinthetreatmentofvariousneovasculardiseases(e.g.,diabeticmacularedema,retinalveinocclusion,choroidalneovascularization)haveshownpromisingresults.Theef cacyandsafetyoftheseagents,eitheraloneorcombinedwithstandardtreatments(e.g.,laserphotocoagulation),anti-in ammatoryagents,orothernon-VEGF-basedantiangiogenictherapies,isactivelyinvestigated.Non-VEGF-drivenpathwaysandgrowthfactorsotherthanVEGFmayplayimportantrolesinpathogenesisandareincludedincertaincombinationtherapieswithVEGFinhibitors.Summary

ThediscoveryofVEGF-A’sroleinthepathogenesisofneovascularoculardiseaseprovidedastrongrationaleforthedevelopmentofanti-VEGF-basedtherapies.Thereisnowampleevidencethatanti-VEGFtherapiesareviabletreatmentoptionsforthesediseases.Nevertheless,large,randomizedcontrolledtrialsarestillawaitedtocon rmearlysafetyandef cacy ndingsfromsmall,open-labelprospectivestudies.Keywords

anti-vascularendothelialgrowthfactortherapy,bevacizumab,neovascularization,pegaptanibsodium,ranibizumab

CurrOpinOphthalmol20:166–174

ß2009WoltersKluwerHealth|LippincottWilliams&Wilkins1040-8738

Introduction

Thesuccessofanti-vascularendothelialgrowthfactor(VEGF)therapiesinneovascularage-relatedmaculardegeneration(AMD)hasspurredinvestigationofsimilartreatmentstrategiesforotherexudativeoculardiseasesdescribedinTable1[1 ,2–7,8 ,9,10,11 ,12 ,13–25].Theseincludeproliferativediabeticretinopathy(PDR)[1 ,3–7],diabeticmacularedema(DME)[2],retinalveinocclusion(RVO)[8 ,9,10,11 ,12 ,13–15],andretino-pathyofprematurity(ROP)[16,17].Currenttreatmentoptionsforthesediseasesandtheircomplicationsarelimited,consistingprimarilyoflaserphotocoagulationandvitrectomy[2,15,26].Althoughthesetreatmentsgenerallyreducelossofvisualacuity,particularlyforpatientswithclinicallysigni cantDME,theyaredestructive(e.g.,laser),associatedwithundesirablesideeffects,andtreatonlythelaterstagesofthedisease[2].

1040-8738ß2009WoltersKluwerHealth|LippincottWilliams&Wilkins

Vascularendothelialgrowthfactor-targetedtherapies

Earlypreclinical[27–30]andclinical[31–34]studieshaveimplicatedVEGFasamajorfactorinthepatho-genesisofneovasculareyediseases,buildingtheration-aleforfurtherinvestigationofthetherapeuticpotentialofVEGF-targetedagents.Anti-VEGF-basedtherapiescur-rentlyunderinvestigationfortheiref cacyandsafetyinneovasculardiseasesotherthanAMDincludetheapta-mer,pegaptanibsodium;theVEGF-speci cantibodies,ranibizumab,andbevacizumab;theimmunoglobulinG(IgG)-VEGFreceptorfusionproteinVEGFtrap;andthesmallinterferingRNA(siRNA)bevasiranib(Table2).Additionally,certainantiangiogeniccorticosteroidsthatdonotspeci callytargetVEGF,suchastriamcinolone,dexamethasone,and uocinoloneacetonidearealsobeingusedandevaluatedforoculardiseases.

DOI:10.1097/ICU.0b013e328329d173

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email